These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32406335)

  • 1. Lack of association between a disease-susceptible single-nucleotide polymorphism, rs2230926 of
    Matsuoka H; Kabata D; Taura A; Matsui T; Takahi K; Hirano F; Katayama M; Okamoto A; Suenaga Y; Suematsu E; Yoshizawa S; Ohmura K; Ito S; Takaoka H; Oguro E; Kuzuya K; Okita Y; Udagawa C; Yoshimura M; Teshigawara S; Harada Y; Isoda K; Yoshida Y; Ohshima S; Tohma S; Saeki Y
    Scand J Rheumatol; 2020 May; 49(3):253-255. PubMed ID: 32406335
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
    Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
    Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful switching treatment of adalimumab for refractory pyoderma gangrenosum in a patient with rheumatoid arthritis with prior use of tumour necrosis factor inhibitors: A case report and review of the literature.
    Ohmura SI; Homma Y; Hanai S; Otsuki Y; Miyamoto T
    Mod Rheumatol Case Rep; 2023 Jan; 7(1):9-13. PubMed ID: 35285489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of association of TNFA, TNFRSF1B and TNFAIP3 gene polymorphisms with response to anti-tumor necrosis factor therapy in Japanese patients with psoriasis.
    Ito M; Hirota T; Momose M; Ito T; Umezawa Y; Fukuchi O; Asahina A; Nakagawa H; Tamari M; Saeki H
    J Dermatol; 2020 Apr; 47(4):e110-e111. PubMed ID: 31872456
    [No Abstract]   [Full Text] [Related]  

  • 5. TNFAIP3 rs2230926 polymorphisms in rheumatoid arthritis of southern Chinese Han population: a case-control study.
    Hao G; Li Y; Liu J; Wo M
    Int J Clin Exp Pathol; 2014; 7(12):8958-61. PubMed ID: 25674272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept.
    Gholami A; Azizpoor J; Aflaki E; Rezaee M; Keshavarz K
    Biomed Res Int; 2021; 2021():4450162. PubMed ID: 34877355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
    BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations Between TNFAIP3 Gene Polymorphisms and Rheumatoid Arthritis Risk: A Meta-analysis.
    Zhang L; Yuan X; Zhou Q; Shi J; Song Z; Quan R; Zhang D
    Arch Med Res; 2017 May; 48(4):386-392. PubMed ID: 28888761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma.
    Kedra J; Seror R; Dieudé P; Constantin A; Toussirot E; Kfoury E; Masson C; Cornec D; Dubost JJ; Marguerie L; Ottaviani S; Grados F; Belkhir R; Fain O; Fautrel B; Philippe P; Piperno M; Combe B; Lambotte O; Richez C; Sellam J; Sené T; Denis G; Lequerre T; Lazure T; Mariette X; Nocturne G
    Joint Bone Spine; 2022 Oct; 89(5):105390. PubMed ID: 35490943
    [No Abstract]   [Full Text] [Related]  

  • 10. Validation of a Bioassay for Predicting Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis.
    Ho CH; Silva AA; Giles JT; Bathon JM; Solomon DH; Liao KP; Ho IC
    Arthritis Rheumatol; 2021 Jun; 73(6):1086-1087. PubMed ID: 33426780
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative persistence of the TNF antagonists in rheumatoid arthritis--a population-based cohort study.
    Fisher A; Bassett K; Wright JM; Brookhart MA; Freeman H; Dormuth CR
    PLoS One; 2014; 9(8):e105193. PubMed ID: 25141123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.
    Favalli EG; Becciolini A; Carletto A; Conti F; Amato G; Fusaro E; Quartuccio L; Egan CG; Lo Monaco A; Benucci M; Salaffi F; Semeraro A; Parisi S; Ceccarelli F; Piazza I; Foti R
    Rheumatol Int; 2020 Feb; 40(2):263-272. PubMed ID: 31435754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the influence of Fc-γ receptor polymorphisms on biologics' pharmacokinetics in Tunisian rheumatoid arthritis patients.
    Mahmoud I; Moalla M; Ben Tekaya A; Charfi R; Rouached L; Bouden S; Tekaya R; Saidane O; Abdelmoula L; Sfar I
    Br J Clin Pharmacol; 2023 Jun; 89(6):1834-1843. PubMed ID: 36609675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct Comparative Effectiveness Among 3 Anti-Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis.
    Santos-Moreno P; Sánchez G; Gómez D; Bello-Gualtero J; Castro C
    J Clin Rheumatol; 2016 Mar; 22(2):57-62. PubMed ID: 26886438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of a nonsynonymous single-nucleotide polymorphism in TNFAIP3 with systemic lupus erythematosus and rheumatoid arthritis in the Japanese population.
    Shimane K; Kochi Y; Horita T; Ikari K; Amano H; Hirakata M; Okamoto A; Yamada R; Myouzen K; Suzuki A; Kubo M; Atsumi T; Koike T; Takasaki Y; Momohara S; Yamanaka H; Nakamura Y; Yamamoto K
    Arthritis Rheum; 2010 Feb; 62(2):574-9. PubMed ID: 20112363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
    García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
    Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients.
    Hamann PDH; Pauling JD; McHugh N; Shaddick G; Hyrich K;
    Rheumatology (Oxford); 2019 Dec; 58(12):2162-2169. PubMed ID: 31155669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission and low disease activity matrix tools: results in real-world rheumatoid arthritis patients under anti-TNF therapy.
    Ganhão S; Lucas R; Fonseca JE; Santos MJ; Gonçalves DR; Madeira N; Silva C; Dourado E; Freitas R; Rodrigues J; Azevedo S; Rocha TM; Ferreira RM; Garcia S; Fernandes BM; Prata AR; Couto M; Torres RP; Cunha I; Costa L; Bernardes M
    Acta Reumatol Port; 2020; 45(4):245-252. PubMed ID: 33420771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis.
    Zhou M; Xu R; Kaelber DC; Gurney ME
    PLoS One; 2020; 15(3):e0229819. PubMed ID: 32203525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three single nucleotide polymorphisms of TNFAIP3 gene increase the risk of rheumatoid arthritis.
    Shen N; Ruan Y; Lu Y; Jiang X; Sun H; Gao G; Nong L; Ren K
    Oncotarget; 2017 Mar; 8(13):20784-20793. PubMed ID: 28199970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.